How GLP-1 Drugs Could Revolutionize Retirement
The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...
Medscape1d
New GLP-1 Data Reinforce CV Benefit
Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...
Yahoo Finance3d
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033
Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...
GLP-1 receptor agonists could hold promise for opioid use disorder treatment
Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...
People are microdosing Ozempic, aka GLP-1, in the name of wellness. We asked experts to weigh in on the benefits
Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...
Medscape9d
GLP-1 Reduces Recurrent Ischemic Stroke in Type 2 Diabetes
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
FoodBusinessNews3d
Maneuvering in the GLP-1 era
ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...
healthday8d
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
Granules eyes foray into peptide segment, CDMO business with ₹192 cr. acquisition of Swiss firm
Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation (CDMO) business with a ₹192.5 crore (CHF 20 million) acquisition of Swiss ...
Daily6d
SGLT2 Inhibitors and GLP-1 Receptor Agonists Linked to Fewer COPD Exacerbations in diabetes patients with COPD: JAMA
Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033
Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...